NetWorth
LeaderPortfolio
Baker
Felix Baker
Rank #1258
UNITED STATES•Finance & Investments•Biotech investing

Felix Baker

Net Worth
$3.393B
0% (24h)
Felix Baker is a prominent figure in the biotechnology investment sector, co-founding Baker Bros. Advisors in 2000. His career began in 1994 with a biotechnology investment partnership with the Tisch Family. Baker's expertise in biotech investing has led to a current estimated net worth of $3.4 billion. He is a director for several biotechnology companies and a Stanford University alumnus with a Ph.D. in immunology.

How to read Felix Baker's profile

Public net-worth figures are estimates. They combine observable inputs—typically listed equity, disclosed transactions, and market prices—with editorial judgment where filings are incomplete (for example, private holdings, debt, or cross-holdings). For Felix Baker, we anchor the narrative to Biotech investing and Biotech investing, then update the headline number as markets move. The chart on this page is meant to show trajectory, not a certified balance sheet.

When you see $3.393B alongside global rank #1258, interpret it as our best synthesis of widely cited ownership and price signals—not a claim about cash on hand. Estimates can diverge from other publishers because of different treatment of options, trusts, charitable vehicles, or illiquid assets. We document the general approach in methodology and welcome corrections via corrections.

Country (UNITED STATES) and career milestones on this page are curated for reader context; they should be verified against primary sources when used for research. Editorial metadata for this profile is refreshed on a rolling basis, with deeper audits at least annually (last noted cycle: 2026).

Looking for depth? When available, the dossier and timeline sections below add long-form context beyond the headline number—prioritize those modules when evaluating claims about strategy, controversies, or philanthropic commitments.

The Full Dossier

Early Life and Education

Felix Baker was born in March 1969. He graduated from Stanford University with a B.S. in Biology and a Ph.D. in Immunology, having also completed two years of medical school. His academic background provided a solid foundation for his career in biotechnology.

Rise to Success

Baker's career in finance began in 1994, with a biotechnology investment partnership with the Tisch family. In 2000, he co-founded Baker Bros. Advisors with his brother, Julian Baker. The firm is a New York-based hedge fund specializing in biotechnology investments. The firm's success is reflected in its management of over $18 billion in assets as of March 2025. Baker's firm has been noted for its strong returns, with an estimated $8 billion gain from an early investment in Seagen.

Key Business Strategies

Baker Bros. Advisors focuses on long-term value creation within the biotech sector through a research-driven strategy, often backing early-stage companies. The firm's approach includes deep scientific due diligence and holding positions through clinical trial phases.

Philanthropy

Felix Baker serves on the advisory council that oversees the interdisciplinary biosciences institutes at Stanford, including Bio-X, the Neurosciences Institute, and ChEM-H. The firm has a reputation for a personalized approach to wealth management and for delivering solutions tailored to client needs.

Career Timeline

2000

Co-founded Baker Bros. Advisors

Co-founded Baker Bros. Advisors, a hedge fund specializing in biotechnology investments, with his brother Julian Baker.

1994

Biotechnology Investment Partnership

Began a biotechnology investment partnership with the Tisch family.

Philanthropic Impact

EducationUnknown

Stanford University Support

Serves on advisory councils for Stanford's biosciences institutes.

Key Business Ventures & Holdings

CompanyStakeValue
Madrigal Pharmaceuticals, Inc.——
ACADIA Pharmaceuticals Inc.——
BeOne Medicines AG——
Incyte Corporation——
Insmed Incorporated——

Net Worth History

In-Depth Analysis

Early Life and Education

Felix Baker was born in March 1969. He graduated from Stanford University with a B.S. in Biology and a Ph.D. in Immunology, having also completed two years of medical school. His academic background provided a solid foundation for his career in biotechnology.

Rise to Success

Baker's career in finance began in 1994, with a biotechnology investment partnership with the Tisch family. In 2000, he co-founded Baker Bros. Advisors with his brother, Julian Baker. The firm is a New York-based hedge fund specializing in biotechnology investments. The firm's success is reflected in its management of over $18 billion in assets as of March 2025. Baker's firm has been noted for its strong returns, with an estimated $8 billion gain from an early investment in Seagen.

Key Business Strategies

Baker Bros. Advisors focuses on long-term value creation within the biotech sector through a research-driven strategy, often backing early-stage companies. The firm's approach includes deep scientific due diligence and holding positions through clinical trial phases.

Philanthropy

Felix Baker serves on the advisory council that oversees the interdisciplinary biosciences institutes at Stanford, including Bio-X, the Neurosciences Institute, and ChEM-H. The firm has a reputation for a personalized approach to wealth management and for delivering solutions tailored to client needs.

Data Sources & Methodology

Figures for Felix Baker are synthesized from the sources below and cross-checked against our net worth methodology. Estimates may lag market moves; see corrections to report discrepancies.

You may also like

HubAll BillionairesHubGlobal RankingsHubNewsroom